Cognitive Decline in Nasopharyngeal Carcinoma Survivors with Post-Radiation Epilepsy: A Prospective Cohort Study.

IF 4.5 2区 医学 Q1 ONCOLOGY
Cancers Pub Date : 2025-06-13 DOI:10.3390/cancers17121976
Kejia Liu, Yaxuan Pi, Yingying Zhu, Dong Pan, Zongwei Yue, Yanting Chen, Lianhong Yang, Yituan Xie, Yuhua Huang, Yamei Tang, Yongteng Xu, Xiaoming Rong
{"title":"Cognitive Decline in Nasopharyngeal Carcinoma Survivors with Post-Radiation Epilepsy: A Prospective Cohort Study.","authors":"Kejia Liu, Yaxuan Pi, Yingying Zhu, Dong Pan, Zongwei Yue, Yanting Chen, Lianhong Yang, Yituan Xie, Yuhua Huang, Yamei Tang, Yongteng Xu, Xiaoming Rong","doi":"10.3390/cancers17121976","DOIUrl":null,"url":null,"abstract":"<p><p><b>Purpose:</b> Cognitive decline is a major concern for nasopharyngeal carcinoma (NPC) survivors after radiotherapy (RT). We assessed whether the rates of cognitive decline in NPC survivors differed depending on the presence of epilepsy. <b>Methods:</b> Based on an ongoing prospective cohort study (NCT03908502), we included consecutive NPC patients with a history of radiotherapy who underwent a baseline and follow-up cognition assessment between January 2005 and December 2023. Patients who had a confirmed diagnosis of epilepsy before radiotherapy, had intracranial brain metastasis during follow-up, lacked baseline major clinical data, or lacked follow-up cognitive assessment of longer than six months were excluded. The outcome was cognitive function assessed by the Chinese version of the Montreal Cognitive Assessment (MoCA), with assessments being performed every 6 months through face-to-face interviews. Linear mixed-effect models were used to analyze the progression rate of MoCA scores by epilepsy status (incident, prevalent, or no epilepsy). <b>Results:</b> A total of 521 patients with a median follow-up period of 3.96 years were included in our study. The rate of decline in MoCA was significantly faster in patients with prevalent epilepsy compared with no epilepsy after adjusting for demographics, health behaviors, tumor-related history, complications, anti-seizure medication, and inflammatory blood index (estimate: -1.407; 95%CI: -2.419, -0.412; <i>p</i> = 0.007). However, the cognitive decline rate was similar in the incident epilepsy group compared with that in the non-epilepsy group (<i>p</i> = 0.126). Subgroup analysis showed that there was no significant difference in the effect of epilepsy status on cognitive deterioration among subgroups stratified by the pre-planned covariates. <b>Conclusions:</b> Global cognitive function declined more rapidly in NPC patients with prevalent epilepsy. The control of seizure attacks may be valuable to mitigate cognitive decline.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 12","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12191416/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers17121976","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Cognitive decline is a major concern for nasopharyngeal carcinoma (NPC) survivors after radiotherapy (RT). We assessed whether the rates of cognitive decline in NPC survivors differed depending on the presence of epilepsy. Methods: Based on an ongoing prospective cohort study (NCT03908502), we included consecutive NPC patients with a history of radiotherapy who underwent a baseline and follow-up cognition assessment between January 2005 and December 2023. Patients who had a confirmed diagnosis of epilepsy before radiotherapy, had intracranial brain metastasis during follow-up, lacked baseline major clinical data, or lacked follow-up cognitive assessment of longer than six months were excluded. The outcome was cognitive function assessed by the Chinese version of the Montreal Cognitive Assessment (MoCA), with assessments being performed every 6 months through face-to-face interviews. Linear mixed-effect models were used to analyze the progression rate of MoCA scores by epilepsy status (incident, prevalent, or no epilepsy). Results: A total of 521 patients with a median follow-up period of 3.96 years were included in our study. The rate of decline in MoCA was significantly faster in patients with prevalent epilepsy compared with no epilepsy after adjusting for demographics, health behaviors, tumor-related history, complications, anti-seizure medication, and inflammatory blood index (estimate: -1.407; 95%CI: -2.419, -0.412; p = 0.007). However, the cognitive decline rate was similar in the incident epilepsy group compared with that in the non-epilepsy group (p = 0.126). Subgroup analysis showed that there was no significant difference in the effect of epilepsy status on cognitive deterioration among subgroups stratified by the pre-planned covariates. Conclusions: Global cognitive function declined more rapidly in NPC patients with prevalent epilepsy. The control of seizure attacks may be valuable to mitigate cognitive decline.

放疗后癫痫鼻咽癌幸存者的认知能力下降:一项前瞻性队列研究。
目的:认知能力下降是鼻咽癌(NPC)放射治疗(RT)后的主要问题。我们评估了鼻咽癌幸存者的认知衰退率是否因癫痫的存在而有所不同。方法:基于一项正在进行的前瞻性队列研究(NCT03908502),我们纳入了2005年1月至2023年12月期间接受基线和随访认知评估的有放疗史的连续鼻咽癌患者。排除放疗前确诊为癫痫、随访期间出现颅内脑转移、缺乏基线主要临床资料或缺乏随访超过6个月的认知评估的患者。结果采用中文版蒙特利尔认知能力评估(MoCA)评估认知功能,每6个月通过面对面访谈进行一次评估。采用线性混合效应模型分析MoCA评分随癫痫状态(发作、流行或无癫痫)的进展率。结果:共纳入521例患者,中位随访期3.96年。在调整了人口统计学、健康行为、肿瘤相关史、并发症、抗癫痫药物和炎症血指数后,流行癫痫患者的MoCA下降速度明显快于无癫痫患者(估计:-1.407;95%ci: -2.419, -0.412;P = 0.007)。然而,癫痫发作组与非癫痫组的认知能力下降率相似(p = 0.126)。亚组分析显示,按预计划协变量分层的亚组中,癫痫状态对认知恶化的影响无显著差异。结论:鼻咽癌伴癫痫的患者整体认知功能下降更快。控制癫痫发作可能对减轻认知能力下降有价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancers
Cancers Medicine-Oncology
CiteScore
8.00
自引率
9.60%
发文量
5371
审稿时长
18.07 days
期刊介绍: Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信